B-Cell Depletion

Biomarker

Related News

Eli Lilly Acquires Orna Therapeutics for $2.4 Billion to Advance Circular RNA Platform

Feb 26, 2026

Eli Lilly announced the acquisition of Orna Therapeutics for up to $2.4 billion on February 9, 2026, gaining access to proprietary circular RNA technology and an "in vivo" CAR-T platform for immunology and oncology applications.

Janux Therapeutics Doses First Patient in Phase 1 Trial of JANX011 for Autoimmune Diseases

Feb 17, 2026

Janux Therapeutics has dosed the first participant in a Phase 1 clinical trial of JANX011, a CD19-targeted bispecific candidate designed using its ARM platform for autoimmune disease treatment.